Cross-model metabolomic signatures of dietary anti-inflammatory polyphenols in nutraceutical development: a systematic review
This systematic review maps metabolomic signatures of dietary polyphenols across multiple models, but the submitted text contains no quantitative outcome data to establish effect direction or magnitude.
| Population | Studies across multiple models (human, animal, in vitro) evaluating dietary polyphenols with metabolomic approaches |
|---|---|
| Intervention | Anti-inflammatory dietary polyphenols (flavonoids, phenolic acids, lignans, stilbenes, tannins) |
| Comparator | Not specified in the provided text; presumably polyphenol-free control |
| Outcome | Cross-model metabolomic signatures of anti-inflammatory polyphenols |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Cross-model metabolomic signatures of anti-inflammatory polyphenols | not estimable — in the quantitative data in submitted text | — | Very low | — |
Context
Dietary polyphenols are nutraceutical candidates with proposed anti-inflammatory, antioxidant, and microbiota-modulating properties. Metabolomics enables tracking of biotransformation and mechanisms of action across experimental models. Cross-model metabolomic signatures may inform rational nutraceutical formulation development.
What the study showed
The full text provided corresponds exclusively to the introduction section, repeated identically across methods, results, and discussion. No quantitative outcome data, effect sizes, or 95% CIs are available in the submitted material. The review describes proposed mechanisms — gut microbiota modulation, SCFA production, bacterial membrane interactions — but presents no quantitative synthesis of included studies.
How it was done
Systematic review published in Frontiers in Molecular Biosciences (2026). The stated design is a cross-model systematic review with metabolomic approach. Number of included studies, eligibility criteria, search strategy, data extraction, and risk-of-bias assessment are absent from the submitted text.
Effect magnitude
No effect size can be extracted from the provided text. The submitted material contains no quantitative results.
Risk of bias
The text available for analysis is limited to the introduction; methods, results, and discussion were not provided with distinct content. Risk-of-bias assessment (AMSTAR-2 would be appropriate for systematic reviews) cannot be performed. Heterogeneity across models (human, animal, in vitro) is an expected structural limitation of cross-model reviews.
What this study does NOT prove
Even when complete, this study would not prove clinical efficacy of any specific polyphenol nor establish causality between metabolomic signatures and health outcomes in clinical populations.
In clinical practice
No concrete clinical recommendation can be derived from the text provided. Clinicians should not modify practice based on this partial analysis. When complete, this review may guide selection of metabolomic biomarkers for polyphenol intervention studies.
Limitations
The text available for analysis is limited to the introduction; methods, results, and discussion were not provided with distinct content. Risk-of-bias assessment (AMSTAR-2 would be appropriate for systematic reviews) cannot be performed. Heterogeneity across models (human, animal, in vitro) is an expected structural limitation of cross-model reviews.
What is still missing
RCTs with hard clinical endpoints and integrated metabolomics are required to translate metabolomic signatures into dose and nutraceutical formulation recommendations.
Technical appendix
Version history
- 1.0 · 2026-10-26 — Auto-generated under Evidence Standard v1.0